Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

David Zebley

Colon & Rectal Surgery Abington, PA Medical Doctor

NPI 1780689232 CMS profile 81170

1235 Old York Rd, Ste G20, Abington, PA 19001

Open in the dashboard

General payments

$23,757

38 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, David Zebley of Abington, PA is reported in the CMS Open Payments database as having received $23,757 across 38 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $331 7
2023 General $78 5
2022 General $660 2
2021 General $1,435 7
2020 General $857 2
2019 General $20,396 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Zebley
  • Colon & Rectal Surgery median
  • Middle half of Colon & Rectal Surgery
  • National median

In program year 2025, general payments to David Zebley were reported at $0. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.

Show as a table
Year David Zebley Colon & Rectal Surgery median Middle half National median
2019 $20,396 $443 $125–$2,179 $163
2020 $857 $167 $53–$931 $114
2021 $1,435 $207 $72–$1,272 $132
2022 $660 $341 $111–$1,587 $149
2023 $78 $322 $115–$1,420 $160
2024 $331 $328 $112–$1,354 $164
2025 $0 $317 $109–$1,248 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Olympus Corporation $22,873 16 payments
  2. Ethicon US, LLC $337 10 payments
  3. Lumendi LLC $167 1 payment
  4. Intuitive Surgical, Inc. $127 3 payments
  5. Medtronic, Inc. $81 1 payment
  6. Braintree Laboratories, Inc. $51 2 payments
  7. Smith+Nephew, Inc. $45 1 payment
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $30 2 payments
  9. Johnson & Johnson Health Care Systems Inc. $30 1 payment
  10. Takeda Pharmaceuticals U.S.A., Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $13,650 6 payments
  2. Travel and Lodging $8,064 5 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,260 2 payments
  4. Food and Beverage $783 25 payments
Products named General payments · program years 2019–2024
  1. Enseal $222 6 payments
  2. DiLumen $167 1 payment
  3. Da Vinci Surgical System $127 3 payments
  4. Echelon Powered Circular $86 2 payments
  5. Harmonic $85 2 payments
  6. GI Genius $81 1 payment
  7. OASIS $45 1 payment
  8. GRAFIX PL $45 1 payment
  9. STRAVIX PL $45 1 payment
  10. Echelon Flex $40 2 payments
  11. Other $173 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

78

Median for Colorectal Surgery (Proctology): 106

Drug cost

$2,224

Median for Colorectal Surgery (Proctology): $1,614

Branded share of claims

16.7%

Median for Colorectal Surgery (Proctology): 35.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 13 $2,063
Neomycin Sulfate Generic 24 $114
Metronidazole Generic 41 $46

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,507 Part D prescribers listed as Colorectal Surgery (Proctology); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$177,133

Medicare's payments for the services billed

Medicare patients

487

Average age 73

Services billed

1,154

233 women, 254 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 44%
Cancer 29%
Diabetes 26%
Ischemic heart disease 23%
Chronic kidney disease 21%
Osteoporosis 18%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Colon & Rectal Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record